Which urine marker test provides more diagnostic value in conjunction with standard cytology- ImmunoCyt/uCyt+ or Cytokeratin 20 expression

Diagnostic Pathology

Volumn 4, Issue 1, 2009, Pages

  Soyuer, Isin ^a   Sofikerim, Mustafa ^a   Tokat, Fatma ^a   Soyuer, Serdar ^a   Ozturk, Figen ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68249153267     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-4-20     Document Type: Article

References (28)

1. The quality of life during intravesical bacillus Calmette-Guerin therapy. A Bohle F Balck J von Weitersheim D Jocham, J Urol 1996 155 4 1221 6 10.1016/S0022-5347(01)66224-4 8632536 (Pubitemid 26081200)
2. Natural history and treatment of low and high risk superficial bladder tumors. H Rübben W Lutzeyer N Fischer F Deutz W Lagrange G Giani, J Urol 1988 139 283 5 3339726
3. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. F Millán-Rodríguez G Chéchile-Toniolo J Salvador-Bayarri J Palou F Algaba J Vicente-Rodríguez, J Urol 2000 164 680 4 10.1016/S0022-5347(05)67280-1 10954628
4. A side by side comparison of cytology and biomarkers for bladder cancer detection. GL Schroeder MF Lorenzo-Gomez SH Hautmann MG Friedrich S Ekici H Huland V Lokeshwar, J Urol 2004 172 1123 6 10.1097/01.ju.0000134347.14643.ab 15311054 (Pubitemid 39096484)
5. Detection of bladder cancer using apoint-of-care proteomic assay. HB Grossman E Messing M Soloway K Tomera G Katz Y Berger Y Shen, JAMA 2005 293 810 6 10.1001/jama.293.7.810 15713770 (Pubitemid 40250364)
6. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. S Hautmann M Toma MF Lorenzo Gomez MG Friedrich T Jaekel U Michl GL Schroeder H Huland KP Juenemann VB Lokeshwar, Eur Urol 2004 46 466 71 15363562
7. Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays? FS Krause A Rauch KM Schrott DG Engehausen, World J Urol 2006 24 418 22 10.1007/s00345-006-0086-y 16688457 (Pubitemid 44304939)
8. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. M Lodde C Mian E Comploj S Palermo E Longhi M Marberger A Pycha, Urology 2006 67 950 4 10.1016/j.urology. 2005.11.057 16698355 (Pubitemid 43956447)
9. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. C Mian K Maier E Comploj M Lodde L Berner L Lusuardi S Palermo F Vittadello A Pycha, Cancer 2006 108 60 5 10.1002/cncr.21712 16411183 (Pubitemid 43291246)
10. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. B Ttu R Tiguert F Harel Y Fradet, Mod Pathol 2005 18 83 9 10.1038/modpathol.3800262 15389253 (Pubitemid 40128099)
11. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. MI Toma MG Friedrich SH Hautmann KT Jäkel A Erbersdobler A Hellstern H Huland, World J Urol 2004 22 145 9 10.1007/s00345-003-0390-8 14991320 (Pubitemid 41406564)
12. Tumor associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. P Allard Y Fradet B Ttu P Bernard, Clin Cancer Res 1995 1 1195 1202 9815912
13. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Y Fradet C Lockhard, Can J Urol 1997 4 400 5 12735818
14. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and merkel cell carcinomas. M Miettinen, Mod Pathol 1995 8 4 384 8 7567935
15. Tumours of the urinary system. G Sauter MA Knowles A Hartmann, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs Lyon: IARC Press, Eble JN, Sauter G, Epstein JI, Sesterhenn IA, 2004 110
16. Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. WM Murphy MS Soloway AF Jukkola WN Crabtree KS Ford, Cancer 1984 53 1555 1565 10.1002/1097-0142(19840401)53:7<1555::AID- CNCR2820530723>3.0.CO;2-G 6697294
17. Cost effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the follow up of patients with transitional cell carcinoma of the bladder: a decision analytical approach. Y Lotan CG Roehrborn, J Urol 2002 167 75 79 10.1016/S0022-5347(05)65386-4 11743279
18. The accuracy of urinary cytology in daily practice. S Bastacky S Ibrahim SP Wilczynski WM Murphy, Cancer 1999 87 118 128 10.1002/(SICI)1097- 0142(19990625)87:3<118::AID-CNCR4>3.0.CO;2-N 10385442
19. Recent advances in bladder cancer diagnostics. M Sanchez-Carbayo, Clin Biochem 2004 37 562 571 10.1016/j.clinbiochem.2004.05.014 15234237 (Pubitemid 38845019)
20. Current bladder cancer tests: unnecessary or beneficial? MA Simon VB Lokeshwar MS Soloway, Crit Rev Oncol Hematol 2003 47 91 107 10.1016/S1040- 8428(03)00074-X 12900004 (Pubitemid 36945310)
21. Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer. M Sánchez-Carbayo M Urrutia JM Silva R Romaní J García F Alférez JM González deBuitrago JA Navajo, Urology 2000 55 4 526 32 10.1016/S0090-4295(99)00557-9 10736496 (Pubitemid 30157957)
22. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. KC Halling W King IA Sokolova RG Meyer HM Burkhardt AC Halling JC Cheville TJ Sebo S Ramakumar CS Stewart S Pankratz DJ O'Kane SA Seelig MM Lieber RB Jenkins, J Urol 2000 164 1768 75 10.1016/S0022-5347(05)67104-2 11025767
23. Role of uCyt-in the detection and surveillance of urothelial carcinoma. M Lodde C Mian G Negri L Berner N Maffei L Lusuardi S Palermo M Marberger C Brssner A Pycha, Urology 2003 61 243 247 10.1016/S0090-4295(02)02073-3 12559316 (Pubitemid 36151760)
24. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. EM Messing L Teot H Korman E Underhill E Barker B Stork J Qian DG Bostwick, J Urol 2005 174 1238 1241 10.1097/01.ju.0000173918.84006.4d 16145377 (Pubitemid 41318690)
25. Urinary cytokeratin 20 as a marker for transitional cell carcinoma. D Rotem A Cassel N Lindenfeld Y Mecz Y Sova M Resnick A Stein, Eur Urol 2000 37 5 601 4 10.1159/000020199 10765100
26. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? V Buchumensky A Klein R Zemer OJ Kessler S Zimlichman I Nissenkorn, J Urol 1998 160 6 Pt 1 1971 4 9817302
27. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer. S Eissa SF Zohny M Swellam MH Mahmoud TM El-Zayat AM Salem, Clinical Biochemistry 2008 41 1335 1341 10.1016/j. clinbiochem.2008.08.085 18804101
28. Should we screen for bladder cancer in a highrisk population? A cost per life-year saved analysis. Y Lotan RS Svatek AI Sagalowsky, Cancer 2006 107 982 90 10.1002/cncr.22084 16862567 (Pubitemid 44291147)